However, the efficacy of the immune checkpoint blocker pembrolizumab (anti-PD-1) and other ICIs (immune checkpoint inhibitors) have not been investigated in patients with progressive MTC. The gene discussed is PDCD1; the disease is medullary thyroid gland carcinoma.